RJA
APTO

Raymond James & Associates’s Aptose Biosciences, Inc. APTO Stock Holding History

Raymond James & Associates’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-82
Closed -$23.7K – 4023
2023
Q1 		$23.7K Buy
82
+3
+4% +$871 ﹤0.01% 3784
2022
Q4 		$20.6K Buy
79
+51
+182% +$13.7K ﹤0.01% 3793
2022
Q3 		$7K Hold
28
– – ﹤0.01% 3882
2022
Q2 		$9K Hold
28
– – ﹤0.01% 3946
2022
Q1 		$17K Sell
28
-8
-22% -$4.42K ﹤0.01% 4024
2021
Q4 		$22K Sell
36
-9
-20% -$8.46K ﹤0.01% 4023
2021
Q3 		$44K Sell
45
-16
-26% -$20K ﹤0.01% 3927
2021
Q2 		$92K Hold
61
– – ﹤0.01% 3850
2021
Q1 		$165K Sell
61
-6
-9% -$11.9K ﹤0.01% 3666
2020
Q4 		$132K Hold
67
– – ﹤0.01% 3510
2020
Q3 		$180K Buy
67
+9
+16% +$22.4K ﹤0.01% 3254
2020
Q2 		$164K Sell
58
-5
-8% -$16.1K ﹤0.01% 3184
2020
Q1 		$169K Buy
63
+10
+19% +$29.8K ﹤0.01% 3090
2019
Q4 		$136K Buy
+53
New +$69.1K ﹤0.01% 3434

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Raymond James & Associates's APTO Position: Q2 2023 in Review

Raymond James & Associates sold out of Aptose Biosciences, Inc. (APTO) in Q2 2023, closing a stake of 82 shares — an estimated $23.7K sold.

Raymond James & Associates first reported a position in APTO in Q4 2019 and held it in 14 quarters. The position peaked at $180K in Q3 2020. 24 funds tracked by Wall St. Rank hold APTO as of Q2 2023.

  • Raymond James & Associates reported no remaining Aptose Biosciences, Inc. position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 82 Aptose Biosciences, Inc. shares in Q2 2023, an estimated $23.7K.
  • Raymond James & Associates first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 14 quarters.
  • Raymond James & Associates's Aptose Biosciences, Inc. position peaked at $180K in Q3 2020.
  • 24 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.